Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...
Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 27, 2027
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Feb 2027
- Supply of pharmaceutical products for the medicinal combination Lamivudin/Abacavir/Dolutegravir.
- Open House rebate agreements under § 130c(1) SGB V.
Show full summary
This is an Open House supply arrangement by Techniker Krankenkasse for the pharmaceutical product combination Lamivudin/Abacavir/Dolutegravir (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with no individual negotiations and no exclusivity. The contract runs from 01.03.2025 to 28.02.2027 at the latest, but no contract value is provided. Participation and contract documents are only available electronically via the buyer portal, while submission is not allowed through the portal and must be made by email with qualified electronic signature or by post. The notice also states that the publication is not considered a public procurement contract under procurement law, so remedies are directed to social courts rather than procurement review bodies.
Risks
Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...
Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
- Applicant must have its seat in Germany, another EU Member State, or another EEA State.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir
Single lot covering Open House rebate agreements for the medicinal product combination Lamivudin/Abacavir/Dolutegravir. The scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated eligibility conditions. Source: structured data and XML notice.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Lamivudin/Abacavir/Dolutegravir zu schließen.
Value note
Show original TED data
Original lot title
Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Lamivudin/Abacavir/Dolutegravir zu schließen.
Procurement Details
- Publication date
- 20 Jan 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 42947-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...
Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications